Amphastar Pharmaceuticals, Inc. Being Investigated on Behalf of Amphastar Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. for potential violations of federal securities laws. This follows an FDA secondary complete response letter regarding Amphastar's generic teriparatide ANDA, AMP-015.
February 28, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation for potential securities law violations after receiving a secondary CRL from the FDA for its generic teriparatide ANDA, AMP-015.
The investigation by Levi & Korsinsky and the FDA's secondary CRL for AMP-015 suggest potential regulatory and legal challenges for Amphastar, likely impacting investor sentiment negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100